Title page -- Table of Contents -- List of contributors -- Foreword -- Introduction -- Declaration of commercial interest -- References -- Section 1: Transplantation in lymphomas -- Chapter 1: Lymphoma and transplantation: historical perspective -- Brief history of hematopoietic cell transplantation -- History of autologous HCT in non-Hodgkin lymphoma -- History of autologous HCT in Hodgkin lymphoma -- History of allogeneic HCT in lymphoma -- General historical considerations -- References -- Chapter 2: Lymphoma: working committee and data reporting after transplantation in lymphoma -- Introduction -- Registry structure -- Data reporting -- Overcoming challenges to data reporting -- Data quality -- The Lymphoma Working Committee -- Statistical methods -- Selected examples from the CIBMTR Lymphoma Committee -- Value for young investigators -- Value for public and other stakeholders -- Conclusion -- References -- Chapter 3: Use of transplantation in lymphoma: adults -- Introduction -- Hodgkin lymphoma -- Non-Hodgkin lymphoma -- Prognostic tools -- Maintenance therapies -- Novel therapies -- Conclusions -- References -- Chapter 4: Hematopoietic stem cell transplantation for lymphoma in children, adolescents, and young adults -- Introduction -- Principles of autologous and allogeneic HSCT in pediatric lymphomas -- Hodgkin lymphoma -- Lymphoblastic lymphoma -- Anaplastic large-cell lymphoma -- Mature B-cell lymphomas: Burkitt lymphoma, diffuse large B-cell lymphoma, and primary mediastinal B-cell lymphoma -- Future directions -- Conclusions -- References -- Chapter 5: Preparative regimens for lymphoma: autologous hematopoietic stem cell transplantation -- Rationale for chemotherapy dose intensification for disease eradication -- Traditional preparative regimens -- Incorporation of monoclonal antibodies in autologous HCT preparative regimens.

Novel agents used in preparative regimens -- Future directions -- References -- Chapter 6: Preparative regimens for lymphoma: allogeneic hematopoietic stem cell transplantation -- Introduction -- Myeloablative conditioning regimens for lymphomas -- Reduced-intensity conditioning regimens -- Incorporating monoclonal antibodies in preparative regimens for allo-HCT -- Alternative donor sources -- Discussion and future direction -- References -- Chapter 7: Pretransplantation evaluation, comorbidities, and nondisease-related eligibility criteria for transplantation in lymphoma -- Introduction -- Initial steps -- Preparation for transplant center evaluation -- Transplant center evaluation -- Post-evaluation review and final pretransplant process -- References -- Chapter 8: Stem cell mobilization in lymphoma patients -- Introduction -- Methods for mobilization -- Stem cell collection and apheresis -- Poor mobilizers and mobilization failure -- Special populations -- Complications -- Future considerations -- References -- Chapter 9: Allogeneic hematopoietic stem cell transplantation for lymphoma: stem cell source, donor, and HLA matching -- Historical perspective -- Rationale for allogeneic transplantation -- Stem cell source -- HLA matching -- Graft source, HLA matching and impact on transplant outcome -- Conclusion -- References -- Chapter 10: Management of early and late toxicities of autologous hematopoietic stem cell transplantation -- Introduction -- Early toxicities -- Late toxicities -- Conclusions -- Conflict of interest -- Further reading -- References -- Chapter 11: Long-term follow-up of lymphoma patients after allogeneic hematopoietic cell transplantation -- Introduction -- Long-term survival after allogeneic HCT for lymphoma -- Follow-up schedule and duration -- Risk factors for late complications.

Guidelines for screening and prevention of late complications -- Delivery of care for lymphoma survivors -- References -- Chapter 12: First 100 days of the autologous hematopoietic stem cell transplantation process in lymphoma -- Introduction and orientation to transplant process -- Impact of conditioning regimen -- Time to engraftment -- First months after transplantation and back to home -- Reference -- Chapter 13: First 100 days of the allogeneic hematopoietic stem cell transplantation process in lymphoma -- Introduction and orientation to transplant process -- Impact of conditioning regimen -- Time to engraftment -- First months after transplantation -- Beyond first months after transplantation and back to home -- Reference -- Section 2: Management -- Chapter 14: Stem cell transplantation in follicular lymphoma -- Introduction -- Autologous transplant as consolidation for first remission -- Autologous transplant for relapsed follicular lymphoma -- Graft purging -- Allogeneic transplant for follicular lymphoma -- Nonsibling donor allogeneic transplant in follicular lymphoma -- RIC allogeneic versus autologous transplant -- Transformed follicular lymphoma -- Chemorefractory follicular lymphoma -- Post-transplant relapse -- Minimal residual disease detection -- Conclusion -- References -- Chapter 15: Chronic lymphocytic leukemia/small lymphocytic lymphoma -- Introduction -- Indication for transplantation in CLL/SLL -- Timing and preparation of patients for transplantation in CLL/SLL -- Transplant outcome in CLL/SLL -- Management of relapses after transplantation for CLL/SLL -- Novel therapies and their integration in transplantation for CLL/SLL -- Summary -- References -- Chapter 16: Diffuse large B-cell lymphoma -- Introduction -- Indications for transplantation in DLBCL -- Timing and preparation of patients for transplantation in DLBCL.

Autologous hematopoietic cell transplantation for DLBCL -- Allogeneic hematopoietic cell transplantation for DLBCL -- Post-transplantation disease monitoring for DLBCL -- Management of relapses after transplantation for DLBCL -- Novel therapies and their integration in transplantation for DLBCL -- References -- Chapter 17: Mantle cell lymphoma -- Indications for transplantation in mantle cell lymphoma -- Timing and preparation of patients for transplantation in mantle cell lymphoma -- Autologous hematopoietic stem cell transplantation for mantle cell lymphoma -- Allogeneic hematopoietic stem cell transplantation for mantle cell lymphoma -- Post-transplantation disease monitoring for mantle cell lymphoma -- Management of mantle cell lymphoma relapse after transplantation -- Novel therapies and their integration in transplantation for mantle cell lymphoma -- References -- Chapter 18: Hodgkin lymphoma -- Indications for transplantation in Hodgkin lymphoma -- Autologous hematopoietic stem cell transplantation for Hodgkin lymphoma -- Allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma -- Post-transplantation disease monitoring for Hodgkin lymphoma -- Management of relapses after transplantation for Hodgkin lymphoma -- Novel therapies and their integration in transplantation for Hodgkin lymphoma -- References -- Chapter 19: Peripheral T-cell lymphomas -- Indication for transplantation in T-cell lymphoma -- Timing and preparation of patients for transplantation in T-cell lymphoma -- Autologous hematopoietic stem cell transplantation for T-cell lymphoma -- Allogeneic hematopoietic stem cell transplantation for T-cell lymphoma -- Post-transplant disease monitoring in T-cell lymphoma -- Management of relapse after transplantation for T-cell lymphoma -- Novel therapies and their integration in transplantation for T-cell lymphoma.

References -- Chapter 20: Transplantation in Burkitt and lymphoblastic lymphoma -- Introduction -- Burkitt lymphoma (Table 20.1) -- Lymphoblastic lymphoma (Table 20.2) -- Conclusion -- References -- Chapter 21: Transplantation in adult T-cell leukemia/lymphoma -- Introduction -- Clinical presentation and classification -- Treatment options -- Hematopoietic stem cell transplantation for ATL -- Recommendations for ATL therapy -- Conclusion -- References -- Chapter 22: Hematopoietic cell transplantation for HIV-related lymphomas -- Origins and epidemiology of HIV/AIDS -- Highly active antiretroviral therapy -- Cancer risk in patients with HIV/AIDS -- NHL and HL in HIV-infected patients -- Clinical presentation -- Prognosis and treatment of HIV-associated lymphoma -- Autologous hematopoietic cell transplantation for patients with AIDS-related lymphoma -- Mobilization, collection, and management of HPC products from HIV-infected patients -- HIV infection and immunological recovery after transplant -- Allogeneic transplantation: the "Berlin patient" and a path toward a cure for HIV -- Transplant as a platform for gene therapy -- Conclusion -- References -- Addendum -- Chapter 23: Stem cell transplantation for mycosis fungoides/Sézary syndrome -- Epidemiology and clinical presentation -- Pathology -- Staging -- Nontransplant therapies -- Autologous stem cell transplantation -- Allogeneic stem cell transplantation -- Summary and recommendations -- References -- Chapter 24: Role of transplantation in lymphoplasmacytic lymphoma -- Definition and diagnosis: Waldenström macroglobulinemia and lymphoplasmacytic lymphoma -- Epidemiology -- Clinical characteristics at diagnosis and criteria for treatment -- Prognostic factors -- Novel agents -- Initial management: any role for HSCT? -- Management at relapse: when, if at all, is the right time for HSCT?.

Conclusions.